Trial · NCT07912242
Cerebellar Brain Stimulation Plus Language Therapy for People at Risk of Poor Aphasia Recovery After Stroke
NCT07912242, Not applicable, Not yet recruiting, Johns Hopkins University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Cerebellar Brain Stimulation Plus Language Therapy for People at Risk of Poor Aphasia Recovery After Stroke. Trials, record NCT07912242. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912242
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cerebellar Brain Stimulation Plus Language Therapy for People at Risk of Poor Aphasia Recovery After Stroke
- NCT number
- NCT07912242
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Johns Hopkins University
- Conditions
- Aphasia, Stroke, Anomia
- Interventions
- Cathodal cerebellar transcranial direct current stimulation, Computerized language therapy
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Western Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ) | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | The WAB-R AQ is a composite measure of overall language impairment, with scores ranging from 0 to 100; higher scores indicate milder aphasia (better outcome). Change from baseline to 6 months post-stroke is compared between the early intervention group (after treatment) and the wait-list group (before treatment). |
| Primary | Mean Absolute Error Between Predicted and Observed 12-Month Western Aphasia Battery-Revised Aphasia Quotient | 12 months post-stroke | Mean absolute difference, in WAB-R AQ points (scale 0 to 100), between the machine learning model's predicted 12-month Western Aphasia Battery-Revised Aphasia Quotient (generated from acute-phase data) and the observed 12-month score. Lower values indicate more accurate prediction. |
| Secondary | Percentage of Treatment Items Produced Correctly | During treatment, up to one week post final treatment session (about 4 to 6 weeks after treatment starts) | Percentage of items trained during treatment that are produced correctly, scored 0 to 100%; higher values indicate better performance. |
| Secondary | Change in Number of Content Units in Picture Description | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | Total number of content units (accurate, relevant pieces of information) produced when describing the Modern Cookie Theft picture and the Precarious Painter picture. Higher values indicate more informative discourse. |
| Secondary | Change in Syllables per Content Unit in Picture Description | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | Number of syllables produced per content unit in the same picture descriptions |
| Secondary | Change in Communication Activities of Daily Living, Third Edition (CADL-3) Total Score | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | The Communication Activities of Daily Living, Third Edition measures everyday functional communication in people with aphasia. Total raw score ranges from 0 to 100; higher scores indicate better functional communication. |
| Secondary | Change in General Health Questionnaire (GHQ) Total Score | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | The General Health Questionnaire (Goldberg and Hillier) measures psychological distress and emotional well-being. Items are rated using 0 to 3 Likert scale, giving a total score from 0 to 84; higher scores indicate greater psychological distress (worse outcome). |
| Secondary | Change in Stroke and Aphasia Quality of Life Scale (SAQOL-39) Mean Score | Baseline (approximately 3 months post-stroke) and 6 months post-stroke | The Stroke and Aphasia Quality of Life Scale-39 measures health-related quality of life after stroke and aphasia. Mean score ranges from 1 to 5; higher scores indicate better quality of life. |
| Secondary | Change in Resting-State Functional Connectivity Between Cortical Language Regions and the Right Cerebellum | Baseline (approximately 3 months post-stroke), 6 months, and 9 months post-stroke | Resting-state functional connectivity (correlation coefficient of oxygenated hemoglobin signals) between cortical language regions and the right cerebellum, measured with functional near-infrared spectroscopy (fNIRS). Higher values indicate stronger connectivity. |
| Other | Western Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ) at 9 Months Post-Stroke | 9 months post-stroke | The WAB-R AQ is a composite measure of overall language impairment (range 0 to 100; higher scores indicate milder aphasia). Compared between groups to explore the effect of treatment timing (treatment starting about 3 versus 6 months post-stroke). |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| T32HD007414 | Research Training in Rehabilitation for Brain Injury and Neurological Disability | BASTIAN, AMY J. | HUGO W. MOSER RES INST KENNEDY KRIEGER | EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT | 1991 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912242
GET https://conductscience.org/api/trials/v1/NCT07912242/registered